Literature DB >> 32662309

The value of a first MRI and targeted biopsies after several years of active surveillance for low-risk prostate cancer - results from the SAMS trial.

Stefan Carlsson1,2, Ola Bratt3, Dushanka Kristiansson4, Fredrik Jäderling2,5.   

Abstract

OBJECTIVE: To assess the value of a first MRI examination and image-fusion-guided biopsies in men with low-risk prostate cancer who have been on active surveillance (AS) for several years with no signs of progression. PATIENTS AND METHODS: All 45 participants from two centers who had not previously had an MRI were included. They had been on AS for T1c Gleason score 6 prostate cancer for 2.6 to 6.7 years and had 2 to 5 sets of systematic biopsies with a total of 1640 cores. All underwent a bi-parametric MRI, PI-RADS ≥ 3 lesions were targeted with image-fusion-guided biopsies. Primary outcome measure: detection of Gleason score ≥7 cancer.
RESULTS: Twenty-five of the 45 men (56%) had a total of 30 suspicious MRI lesions. The lesion with the highest score was a PI-RADS 3 in 18, a PI-RADS 4 in 5 and PI-RADS 5 in 3 men. Targeted biopsies from the 30 lesions detected Gleason score 7 cancer in 6 men. Of these six cancers, four were located in the apical and one in the anterior/apical part of the prostate. A Gleason score 7 cancer was detected in 3 of 5 men with PSA density >0.15 ng/ml/cm3.
CONCLUSIONS: Even after several years of AS with stable PSA values and many sets of systematic biopsies, a first MRI and targeted biopsies lead to the detection of Gleason score 7 (ISUP 2 and ISUP 3) cancer in a significant proportion of men, particularly among those with a high PSA density.

Entities:  

Keywords:  MRI fusion biopsy; Prostate cancer; active surveillance

Mesh:

Year:  2020        PMID: 32662309     DOI: 10.1080/21681805.2020.1788634

Source DB:  PubMed          Journal:  Scand J Urol        ISSN: 2168-1805            Impact factor:   1.612


  1 in total

1.  Two Decades of Active Surveillance for Prostate Cancer in a Single-Center Cohort: Favorable Outcomes after Transurethral Resection of the Prostate.

Authors:  Sarah Hagmann; Venkat Ramakrishnan; Alexander Tamalunas; Marc Hofmann; Moritz Vandenhirtz; Silvan Vollmer; Jsmea Hug; Philipp Niggli; Antonio Nocito; Rahel A Kubik-Huch; Kurt Lehmann; Lukas John Hefermehl
Journal:  Cancers (Basel)       Date:  2022-01-12       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.